Type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) are increasing globally, with mitochondrial dysfunction being a core component in their development. While a 75g oral glucose tolerance test (OGTT) can be used to diagnose T2D, hepatic metabolic and mitochondrial dysfunction can be assessed using a 13C-methionine breath test (BT). We aimed to evaluate combining these tests for an efficient, non-invasive screening tool.
Methods
On three study days, 26 subjects (11 [43.3%] female, 61± 16 years) subjects underwent either an OGTT, a 13C-methionine BT or both tests combined. Diagnostic outcomes of the individual and combined tests were compared using cumulative 13C percentage dose recovered (cPDR), plasma glucose concentrations and Homeostatic Model Assessment (HOMA)-indexes for insulin resistance and beta-cell function.
Results
In the combined test, cPDR90min was significantly lower (cPDR90min 2.3± 0.2% vs. 5.7± 0.5%; p< 0.0001), accompanied by a rightward shift of the 13C-increase towards later time points. When breath collection of the combined test was extended, cPDR145min (5.7± 0.4%) was practically identical to cPDR90min of the single test (p= 0.99). OGTT results, plasma glucose, and HOMA-indexes did not differ significantly between tests.
Conclusions
Combining a 13C-methionine BT with an OGTT significantly impacts 13C-methionine kinetics, but not OGTT results. A potential mechanism includes a glucose-induced delay of gastric emptying. Combined testing may be feasible when time-adjusted measurements are used, potentially allowing simultaneous screening for both T2D and MASLD-associated mitochondrial dysfunction in clinical practice.
diabetesMASLDmetabolic diseasemethionine kineticsnon-invasive testoral glucoseThe author(s) declared that financial support was not received for this work and/or its publication.section-at-acceptanceClinical DiabetesHighlights
Hepatic mitochondrial dysfunction is central to diabetes and MASLD pathogenesis.
Oral glucose significantly delays 13C-methionine breath test kinetics.
Extending the sampling period in combined testing yields comparable results.
Diagnostic outcomes of the oral glucose tolerance test and HOMA remain unchanged.
A combined approach enables efficient integrated assessment for metabolic disease.
Introduction
Metabolic diseases are an increasing global socioeconomic burden characterized by a high incidence and mortality (1). Obesity, type 2 diabetes (T2D), metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascular disease share several factors in their pathogenesis and represent the majority of cases with metabolic diseases worldwide (1, 2). Both conditions independently increase carotid intima-media thickness, a marker of subclinical atherosclerosis, through systemic low-grade inflammation, insulin resistance, and pro-atherogenic cytokines like IL-6 and TNF-α (3, 4) and significantly increase cardiovascular risk (5). Patients presenting with either T2D or MASLD have a more than twofold increased risk of developing the other, suggesting that in clinical practice, patients with one condition should be screened for the other (6). However, the clinical assessment of metabolic disease and its associated risks can be challenging, especially in borderline cases.
Beyond their independent associations with obesity, both T2D and MASLD are characterized by progressive hepatic mitochondrial dysfunction (7). Recent evidence demonstrates that impaired mitochondrial β-oxidation and oxidative stress represent critical elements in the pathophysiology of both conditions, suggesting that simultaneous assessment of glucose homeostasis and hepatic mitochondrial function could provide integrated mechanistic insights into metabolic disease pathogenesis (8, 9). Hepatic mitochondrial function can be assessed non-invasively in vivo using a 13C-methionine breath test (10). This test can stratify hepatic mitochondrial function and is potentially able to differentiate between MASLD, metabolic dysfunction-associated steatohepatitis (MASH) and MASH cirrhosis (11, 12). In contrast, screening for T2D is often performed using point-of-care plasma glucose or glycated hemoglobin (HbA1c) analysis. However, the American Diabetes Association also recommends a 75g oral glucose tolerance test (OGTT) as first or second line (e.g., in subjects with a HbA1c of 5.7 – 6.4%) diagnostic in subjects with suspected diabetes (13). Given the strong correlation of diabetes with other metabolic diseases and cardiovascular disease, screening for other conditions like MASLD in these subjects could improve early diagnosis and, potentially, patient outcomes. Compared to transient elastography or liver biopsy, both the 13C-methionine breath test and the OGTT are simple and inexpensive tools to screen for the presence of metabolic diseases and are characterized by their capability to do detect even early stages of the disease or dysfunction, respectively. Nonetheless, this cost-effectiveness applies to well-equipped clinical settings but is limited by 13C-isotope availability globally. Moreover, subjects must be fasted for both tests which can hinder their implementation, especially in outpatient settings. Performing these tests simultaneously has not been examined yet. The primary objective of the present study is therefore to evaluate whether combining the two tests alters methionine kinetics and whether time-adjusted measurement might recover comparability to single-test protocols to evaluate if this approach could potentially offer an efficient non-invasive screening tool for metabolic assessment.
Materials and methods
The present study was a monocentric pilot study performed from February to October 2023 at the Department of Internal Medicine of the St. Josef Hospital, University Hospital of the Ruhr University Bochum, Germany. The study was conducted according to the principles of good clinical practice and approved by the local ethics committee before commencement (registration no. 22-7723). Written informed consent was obtained from all subjects before any study procedures were conducted.
Study population
In- and outpatients treated at St. Josef-Hospital Bochum and its adjunct outpatient facilities were eligible if a physician requested either a 13C-methionine breath test or an oral glucose tolerance test (OGTT). The decision to perform either test was made at the physician’s discretion and independent from the study. All potentially eligible subjects were screened for inclusion after scheduling either test, with consecutive recruitment to reduce selection bias. Major inclusion criteria for the study was a body mass index (BMI) ≥ 25 kg/m2. Subjects who exhibited conditions that could potentially affect the absorption of 13C-methionine or glucose from the gastrointestinal tract or affect the exhalation (14) were excluded from the study. Full inclusion and exclusion criteria are reported in Supplementary Table S1.
Screening visit
Participants underwent a physical examination including evaluation of laboratory parameters and determination of the FIB-4 score (15). A thorough medical history was obtained with a focus on cardiovascular, metabolic, and liver conditions.
Interventions
Following the initial screening, participants were invited to three study visits. Each visit, subjects underwent either a 13C-methionine breath test, an OGTT, or a combined test involving both a 13C-methionine breath test and an OGTT. The test sequence always started with the test requested by the physician (either 13C-methionine breath test or OGTT) and was determined by the study personnel. The order of the remaining tests was at random. Subjects were invited to the study site fasted and refraining from nicotine or alcohol for at least eight hours. For the 13C-methionine breath test and the combined test, subjects were asked to avoid 13C-rich food for 2 days (e.g. corn, pineapple, broccoli, sugarcane). For the OGTT and the combined test, participants were instructed to consume a diet containing at least 150 g carbohydrates per day for the three days leading up to the test.
<sup>13</sup>C-methionine breath test
The 13C-methionine breath test is a non-invasive method to assess the mitochondrial function of hepatocytes and may indicate metabolic dysfunction-associated steatohepatitis (MASH) (14, 16). In this test, 2 mg methionine per kg body weight are dissolved in 100 ml of water. Gas-tight sampling breath test bags are prepared, and breath samples are collected every 10 minutes over a 90-minute period (total of 10 bags, t-5 – t90). The analysis is performed on-site by isotope-selective nondispersive infrared spectroscopy (IRIS® system). A baseline breath sample is taken before drinking the 13C-methionine solution. The primary results are expressed as the delta of the 13C/12C-concentration over the baseline (DOB). To quantify the metabolized substrate, the results are expressed as 13C percentage dose recovered (PDR) for each time interval and the cumulative 13C percentage dose recovered (cPDR90min) after 90 minutes. While the 13C-methionine breath test primarily assesses hepatic mitochondrial function, some studies suggest that it has potential for the non-invasive diagnosis of MASH (14). In this context, a cPDR90min of more than 4.2% indicates the absence of MASH. Values below 4.2% suggest the presence of MASH, and those below 3.65% are suggestive for liver fibrosis of higher degree (F2-F3) (14).
Oral glucose tolerance test
The OGTT is a test used to detect impaired glucose metabolism and even early stages of diabetes mellitus. The test was performed in adherence to the current recommendations of the American Diabetes Association (13). A peripheral venous catheter was placed, and subjects were placed in a sitting or reclined position, with the subject refraining from physical activity.
At baseline, two blood samples were drawn before consuming the glucose solution (t-5 and t0). Then, a solution containing 75g of glucose dissolved in 300 ml of water was administered orally (t0). Further blood samples were collected at 60 minutes (t60) and 120 minutes (t120) after oral glucose administration. These blood samples were centrifuged and analyzed for plasma glucose, insulin, and C-peptide. Homeostasis Model Assessment (HOMA) for insulin resistance (HOMA-IR) and β-cell function (HOMA-B) were determined as previously described (17–19).
Combined <sup>13</sup>C-methionine breath test and oral glucose tolerance test
The combined test was performed similar to the procedures outlined above. However, breath samples were collected every 10 minutes over an extended duration of 180 minutes (instead of 90 minutes) to account for potential delayed increase in 13C concentration (e.g., due to glucose-mediated deceleration of gastric emptying) (20). Aside from this, the test protocol remained unchanged.
Safety and adverse events
Patients received detailed informed consent regarding potential adverse effects including dizziness, nausea, sleepiness, polyuria, or blood pressure changes. Subjects were monitored during all test procedures. Adverse events were systematically documented.
Endpoints
The primary endpoint was to determine if there is a difference of ≥ 10% between the 13C-methionine breath test and the combination of an 75g oral glucose tolerance test and a 13C-methionine breath test in the cumulative 13C percentage dose recovered (cPDR) at t = 90 min (cPDR90min). We assumed from previous studies that the caloric load of the OGGT would decelerate gastric emptying velocity (21) and speculated that this would result in a delayed 13C exhalation in the combined test. Consequently, the secondary endpoint was to determine the time (tx) at which the cPDR of the combined test was equal to the cPDR90min of the 13C-methionine breath test without OGTT.
StatisticsPower calculation
Pre-study sample size was estimated using G*Power 3.1.9.7 (22). A study of our group showed a cPDR90min of 6.15 ± 1.2% for healthy controls (14). For the primary endpoint, the 13C-methionine breath test and the combined test were assumed to provide comparable results if results of cPDR90min differ by less than 10% (ΔcPDR = 0.6%). Estimating a standard deviation of 1.2, the effect size was determined as dz = 0.56. We estimated that n = 36 would be sufficient to provide a power (1- β) of 0.9 with α = 0.05. During a pre-specified interim analysis after 26 included subjects, a post hoc power analysis revealed an actual power (1- β) of 1.0 for the primary endpoint, substantially exceeding the pre-specified difference threshold. Given the large effect size (Coehn’s d = 3.2) and the high statistical significance achieved, continued enrollment to n = 36 was unlikely to substantially modify conclusions about primary kinetic differences and recruitment was stopped.
Statistical considerations
The primary endpoint was analyzed using t-test for paired samples. cPDR0min - cPDR90min was analyzed using repeated measures analysis of variance (RM-ANOVA) with Šídák’s multiple comparisons test for post hoc analysis.
Categorical data was analyzed using Fisher´s exact test or χ2 test. Continuous normally distributed data was analyzed using t-test for paired or unpaired samples (the latter with Welch’s correction), analysis of variance or linear models in general. In addition, correlations are to be calculated using Pearson correlation. A linear regression model was used to determine the crossing of the slope of the combined test with the cPDR90min of the 13C-methionine breath test. Results for crossing of curves are presented as mean [95% confidence interval]. Interval between study days is presented as median (min; max). Results are presented as means ± standard error of mean (SEM). Descriptive data is presented as mean ± standard deviation. Statistical significance was defined as p < 0.05. Statistical analyses were performed using GraphPad Prism Version 10 for Windows (GraphPad Software, San Diego, California USA, www.graphpad.com).
Results
From February until October 2023, we screened 32 subjects and included 26 participants (reasons for exclusion: withdrawal of consent after completing first study visit [five subjects], diagnosed T2D at screening [one subject]). Baseline parameters of completers are presented in Table 1. Subjects were mostly male (56.7%), mean age was 61 ± 15.9 years, and all subjects were overweight (17 [65.4%]) or obese (WHO-grade I adiposity: seven [26,9%], WHO-grade II adiposity: two [7.7%], mean BMI: 29.3 [± 3.6] kg/m²). Mean FIB-4 score was 1.4 ± 1.1 and two (7.7%) subjects had scores indicating a high risk of fibrosis (Supplementary Figure S1) (23).
Baseline characteristics of study participants.
Parameter
Unit
Normal limits
Result
Clinical parameters and medical history
Age
years
n/a
61 ± 15.9
Sex
female/male (%female)
n/a
11/15 (42.3%)
Body Mass Index
kg/m²
< 25.0
29.3 ± 3.6
Arterial hypertension
n (%)
n/a
14 (53.8%)
Atrial fibrillation
n (%)
n/a
1 (3.8%)
Previously diagnosed steatotic liver disease
n (%)
n/a
4 (15.4%)
Laboratory parameters
HbA1C
%
4.8 - 6.0
5.6 ± 0.3
mmol/L
29 - 42
38.0 ± 3.7
Creatinine clearance*
ml/min/1.73
> 90
79.4 ± 22.7
GGT
U/L
10 - 71
27.2 ± 18.2
AST
U/L
10 - 50
25.8 ± 6.4
ALT
U/L
10 - 50
25.3 ± 9.6
Bilirubin
mg/dL
< 1.2
0.5 ± 0.3
μmol/L
< 20.52
8.55 ± 5.13
CRP
mg/dL
< 5
5.2 ± 0.6
Albumin
g/L
3.5 - 5.2
4.4 ± 0.3
INR
n/a
0.8 - 1.1
1.0 ± 0.1
FIB-4 score
n/a
< 2.67
1.4 ± 1.1
High-risk FIB-4
n (%)
> 2.67
2 (7.7%)
Medication
Antihypertensives
n (%)
n/a
16 (61.5%)
Antiplatelet drugs
n (%)
n/a
6 (23.1%)
Anticoagulation
n (%)
n/a
2 (7.7%)
Statin
n (%)
n/a
9 (34.6%)
Data are presented as means ± standard deviation, or number and percentage (%) of total. *According to the formula defined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). HbA1C, hemoglobin A1c; GGT, Gamma-glutamyl transferase; AST, Aspartate Aminotransferase; ALT, Alanine transaminase; ALP, Alkaline phosphatase; CRP, C-reactive protein; INR, international normalized ratio; FIB-4, Fibrosis-4 Index.
Further characteristics are displayed in Supplementary Table S3 and S4.
Arterial hypertension was diagnosed in 14 (53.8%) subjects and four (15.4%) had previously confirmed steatotic liver disease. None of the subjects were diagnosed with diabetes mellitus, but ten (38.5%) had prediabetes according to HbA1c (mean HbA1c 5.6 ± 0.3%). History of cardiovascular disease was present in two subjects (stroke). The tests were conducted with a median interval of 9.5 (1–75) days.
<sup>13</sup>C-methionine breath testKinetics
After 90 minutes, cPDR was significantly lower in the combined test as compared to the 13C-methionine breath test (Figure 1A, cPDR90min 2.3 ± 0.2% vs. 5.7 ± 0.5%; p < 0.0001). The slope for cPDR was significantly lower in the combined test, with the slope of the combined test showing a delayed, almost linear increase after 100 min (Figure 1B). Linear regression analysis revealed that the slope of the combined test from 110–180 min (y = 0.069. x – 4.205, r² = 0.999, p < 0.0001) crossed the cPDR90min of the methionine breath test at 144.3 [137.8 to 151.0] min. The estimated cPDR145min ([cPDR150min – cPDR140min]: 2 + cPDR140min) of the combined test (5.7 ± 0.4%) was practically identical to the cPDR90min of the methionine test (ΔcPDR 0.0038 ± 0.47%, p = 0.99).
Cumulative percentage dose rate (cPDR) of the 13C-methionine breath test and the combined test. (A) Shows the cumulative percentage dose rate (cPDR) after 90 min of the 13C-methionine breath test (BT; white circles) and the combined test (grey squares). The horizontal grey lines in panel A display the mean, the vertical grey lines display the standard error of mean (SEM). Data was analyzed using Fisher’s t-test for paired samples. (B) Shows the cPDR over time. Data from 0–90 min (cPDR0min – cPRD90min) was analyzed using repeated measures analysis of variance (RM-ANOVA) with Bonferroni’s correction for post hoc analysis. Significant differences in time points (p < 0.05) were marked with an asterisk. The dashed line marks the mean cPDR of the 13C-methionine BT at 90 minutes (cPDR90min = 5.7%).
Two graphs labeled A and B compare the results of the ¹³C-methionine breath test and a combined test. Graph A shows scattered points with circles for ¹³C-methionine and squares for the combined test, with a significant p-value less than 0.0001. Graph B shows cPDR over time, with circles and squares linked to each test. Notable increases for ¹³C-methionine over 180 minutes are marked with asterisks, indicating significant differences at various intervals.Clinical outcomes
According to the cPDR90min in the 13C-methionine breath test, 18 (69.2%) subjects had results consistent with absence of MASH or fibrosis. In 3 (11.5%) subjects, MASH was present (cPDR90min < 4.2%) and liver fibrosis of higher degree (F2-F3, cPDR90min < 3.65%) was found in 5 (19.2%). Two subjects with an abnormal 13C-methionine breath test also had an abnormal FIB-4 score indicating high probability of fibrosis (Supplementary Figure S1).
As exploratory analysis, the established cPDR cut-offs for the 13C-methionine breath test after 90 minutes were applied to interpretate the cPDR145min of the combined test. Based on the cPDR145min, 21 (80.8%) subjects had results consistent with absence of MASH or fibrosis and 5 (19.2%) had fibrosis. The outcome did not differ significantly between cPDR90min and cPDR145min (p = 0.20). In 6 (23.1%) subjects, the results varied between the two tests (healthy [single test] to fibrosis [combined test]: 2 [7.7%], healthy [single test] to MASH [combined test]: 3 [11.5%]; fibrosis [single test] to healthy [combined test]: 1 [3.8%]). The only parameter that differed significantly between subjects with a different outcome in combined as compared to the single 13C-methionine breath test and those with an unchanged outcome was plasma bilirubin concentration (0.8 ± 0.1 vs. 0.5 ± 0 mg/dL, p = 0.037). Further characteristics are displayed in Supplementary Table S2.
Oral glucose tolerance testGlucose
Plasma glucose concentrations at baseline (Δ 0.15 ± 0.01 mmol/L [2.7 ± 1.4 mg/dL], Figure 2A) and after 120 minutes (Δ 0.56 ± 0.29 mmol/L [10.0 ± 5.3 mg/dL], Figure 2B) were by trend higher in the combined test. Plasma glucose concentrations after 60 minutes were not significantly different (Δ 0.31 ± 0.26 mmol/L [5.5 ± 4.7 mg/dL]).
Results of the oral glucose tolerance test with and without the 13C-methionine breath test. Plasma concentrations of glucose (A, B), insulin (C) and C-peptide (D) after a 75 g oral glucose challenge (oral glucose tolerance test) alone (white circles) or combined with a 13C-methionine breath test (grey squares). Error bars display standard error of mean (SEM). (B) Displays the plasma glucose concentration after 120 minutes for both tests and their delta (Δ) with the P-value being calculated using Student’s t-test for paired samples. Data in (A, C, D) was analyzed using baseline subtracted 2-way analysis of variance (ANOVA) with “Test” representing the overall effect of the intervention, “Time” representing the effect of time and “Test x Time” representing the interaction of intervention and time on plasma concentrations. If “Test” or “Time” were significant (p < 0.05), post hoc (Šídák’s) tests were performed to locate significant differences to single time points (asterisks).
Graphs A to D show data comparing OGTT and Combined test over time. Graph A displays glucose levels; Graph B displays individual glucose data points with p-values. Graph C shows insulin levels with significant p-values noted; Graph D shows C-peptide levels with non-significant test effects stated. All graphs demonstrate changes over 120 minutes.Insulin and C-peptide
Insulin at baseline (Δ 4.0 ± 4.9 pmol/L [0.58 ± 0.71 µU/mL]) and after 60 minutes (Δ 28.8 ± 60.6 pmol/L [4.14 ± 8.72 µU/mL]) did not differ between the tests (Figure 2C). However, after 120 min plasma insulin concentrations were significantly higher in the combined test (Δ 131.1 ± 57.9 pmol/L [18.87 ± 8.33 µU/mL]). For C-peptide, no significant difference was found (baseline: Δ 0.02 ± 0.04 nmol/L [0.06 ± 0.12 ng/mL, 60 minutes: Δ 0.03 ± 0.13 nmol/L [0.08 ± 0.4 ng/mL], 120 minutes: Δ 0.17 ± 0.13 nmol/L [0.52 ± 0.4 ng/mL]; Figure 2D). Results for HOMA IR (3.5 ± 0.5 vs. 3.5 ± 0.5) and HOMA β (127.8 ± 18.0 vs. 161.1 ± 15.7) did not differ between the tests (p = 0.78 and p = 0.11, respectively).
Clinical outcomes
Overall, no statistically significant differences between the outcome of the single OGTT and the combined test were found (Table 2). However, the number of subjects diagnosed with diabetes was numerically higher in the combined test (1 [3.8%] vs. 3 [11.5%], p = 0.61). Details of the subjects diagnosed with diabetes are presented Supplementary Table S5.
Interpretation of the plasma glucose concentrations at 120 min in the oral glucose tolerance test and the combined test.
Result of the test
OGTT
Combined test
p-value
No diabetes
16 (61.5%)
12 (46.2%)
0.40
Impaired fasting glucose
3 (11.5%)
8 (30.8%)
0.17
Impaired glucose tolerance
6 (23.1%)
6 (23.1%)
> 0.99
Both IGT and IFG
0
3 (11.5%)
0.24
Diabetes
1 (3.8%)
3 (11.5%)
0.61
Plasma glucose ≥ 8.6 mmol/L (155 mg/dL)
12 (46.2%)
10 (38.5%)
0.78
Data are presented as number and percentage (%) of total. OGTT, oral glucose tolerance test; IGT, impaired glucose tolerance; IFG, impaired fasting glucose. Statistics, Student’s t-test for paired samples.
Safety outcomes
No adverse or serious adverse events occurred. All 26 subjects completed all three study visits. No episodes of dizziness, nausea, sleepiness, polyuria, or significant blood pressure changes were reported. Some patients reported an unusual taste after ingestion of the 13C-methionine, not fulfilling the criteria of an adverse event.
Discussion
The present study aimed to determine if the combination of a 75 g oral glucose tolerance test and a 13C-methionine breath test alters methionine kinetics and provides results comparable to single-test protocols. The primary finding is that the result of the breath test (cPDR90min) significantly differs between the single and the combined. However, the cPDR145min of the combined test provides comparable results to the cPDR90min of the single test to assess the mitochondrial function of hepatocytes. Furthermore, the diagnostic outcome of the oral glucose challenge is mostly consistent between the tests.
In the combined test, the cPDR90min was significantly lower than the cPDR90min of the single 13C-methionine breath test (Figure 1A). The curve is clearly less steep, suggesting a delayed metabolism or absorption of 13C-methionine. A potential mechanism for the delayed increase in cPDR could be the metabolic challenge for hepatocytes associated with the glucose challenge. In contrast to this theory, no influence of methionine on glucose-6-phosphatase in vitro (primary bovine neonatal hepatocytes) was found, however, mitochondrial phosphoenolpyruvate carboxykinase expression was marginally decreased (24). The most likely reason for the delayed increase in exhaled 13C appears to be delayed gastric emptying, induced by the caloric load of the OGTT. The velocity of gastric emptying is a major determinant of the postprandial rise in plasma glucose (25). Importantly, it is dependent on the size and composition of meal with higher caloric content significantly slowing the rate of gastric emptying (26). The increase of macronutrient content of the solution by adding glucose certainly decelerated gastric emptying in the present study, resulting in a delayed absorption of the 13C-methionine in the small intestine, thus a delayed hepatic metabolism and ultimately a delayed 13C-exhalation. While there is a large interindividual variation in the velocity of gastric emptying (especially in obesity and diabetes (27)), the intraindividual variation is less pronounced. The velocity of gastric emptying decreases with increasing caloric content of the ingested food, ranging from 1–4 kcal per minute (28), with differences between women and men and different ethnic groups. However, since gastric emptying was not assessed in the present study, this mechanism, although being highly likely, remains speculative. Future studies should evaluate alternative or complementary pathways explaining the observed effect, including altered intestinal absorption, acute hepatic metabolic competition, hormonal modulation by GLP-1, GIP and insulin or microbiota-related changes.
The 13C-methionine breath test quantifies hepatic mitochondrial dysfunction but may not capture all effects of MASLD on cardiovascular disease and risk (3, 5). Beyond hepatic mitochondrial assessment, patients with preserved 13C-methionine breath test results may still be at significant cardiovascular risk (quantified for example by an carotid wall thickening) due to subclinical inflammation (29). Conversely, abnormal breath test results strongly predict increased carotid artery wall thickness and cardiovascular risk. Consequently, the combined OGTT/13C-methionine test should be understood as potential screening tool and certainly does not replace comprehensive cardiovascular risk assessment (including parameters like carotid media thickness, lipid profile, blood pressure) in MASLD patients (30).
The combined test protocol showed an excellent safety profile at the 2 mg/kg methionine dose. Unlike prior studies using higher doses (100 mg/kg), which reported substantial dizziness, nausea, somnolence, polyuria, and hemodynamic changes (31), none of these adverse effects occurred here, confirming favorable tolerability. Combined with the non-invasive nature of both tests, this supports further studies investigating real-world clinical feasibility for metabolic screening.
Overall, the oral glucose tolerance tests were not significantly different between the tests (Figure 2). However, the trend to higher plasma glucose concentrations after 120 min with an increase of ~ 4.1 ± 3.5% (mean ± SEM) versus the single test must be considered. Both, postprandial plasma glucose concentrations and the rate of gastric emptying are depending on the level of glycaemia (27). Since plasma glucose concentrations at baseline were higher in the combined test (~ 2.6 ± 1.3% [mean ± SEM]), the small difference in baseline plasma glucose concentration might have impacted the plasma glucose concentrations during the test. In contrast, an influence of the caloric content of methionine (approximately 1.7 kJoule [0.4 kcal]) per 100 mg, corresponding to ~ 0.1 g glucose) is rather unlikely. Other factors known to influence plasma glucose excursions after an oral glucose challenge (i.e., diet, activity level, stress, sleep, or physiological variability including changes in body weight) could potentially influence the outcome of glucose tolerance tests. These factors were not assessed systematically. While these influences explain the slight intertest variability, the overall result remained unchanged. Also, C-peptide, HOMA IR and HOMA β were consistent between the tests. This confirms the validity of the combined test as compared to an OGTT as one standard for the diagnosis of T2D. When discussing the results of the present study and deviations between the single tests and the combined test, the sensitivity and specificity of each test must be considered. Since neither the OGTT nor the 13C-methionine breath test provide a 100% sensitivity and specificity, the differences observed in the present study may easily be explained by the limitations of the individual test.
Liver biopsy remains the only method to allow for definite diagnosis of metabolic liver disease including steatohepatitis and the only method to evaluate relevant microscopic features like ballooning or lobular inflammation (23). However, current guidelines also appreciate that liver biopsy is not required for clinical management of individuals with MASLD in most cases (23). Currently, several non-invasive options to assess liver function, steatosis, fibrosis and cirrhosis in subjects with metabolic syndrome/suspected MASLD are available (32). These include serum biomarkers (33) and elastography utilizing ultrasound or magnetic resonance imaging (MRI) techniques (34). However, some tests may be difficult to perform in severely obese subjects, cases with contraindication for MRI or in subjects with rib-injuries (34). The advantages of 13C breath tests are that they examine in vivo the hepatic mitochondrial function and therefore offer a different approach to assessment of liver diseases compared to the above-mentioned methods. Furthermore, breath tests are cost-effective (e.g., compared to MRI) and can easily be implemented in clinical practice (35). The test is non-invasive and non-radioactive. Impaired liver function from various causes, such as drug-related acute liver toxicity, oxidative stress and impaired hepatic mitochondrial oxidation, can be detected (36). Since mitochondria are essential for fatty acid oxidation, lipogenesis and gluconeogenesis, their dysfunctionality is appreciated as key factor in the pathophysiology of several metabolic diseases (8). It should also be appreciated that obesity and metabolic syndrome are risk factors for both, T2D and MASLD (37). Consequently, the advantage of combining a screening method for both diseases is obvious. However, while the present approach allows for easy follow-up or routine liver function testing it was not formally validated in the present pilot study and needs further evaluation in an independent cohort or alongside established MASLD and diabetes diagnostic comparators.
The present study has limitations that should be considered. The study design was not blinded to the participant or the investigators. Also, clinical and laboratory differences between the tests were not assessed. Given the maximum interval between tests of up to 75 days, these differences could have a potential impact on the tests results (e.g., the weight loss of one participant most probably leading to an improved OGTT result). However, most tests were conducted within 11 days and significant clinical or laboratory changes in this interval appear unlikely. Of note, the present study did not evaluate the efficacy and reliability of the 13C-methionine breath test for diagnosing MAFLD or assessing liver function in comparison to other non-invasive diagnostic procedures or liver biopsy. While this was not the aim of the present study, no further conclusions on the performance of the 13C-methionine breath test to other non-invasive methods can be drawn. Furthermore, adding an intervention to investigate changes in cPDR90min would have provided valuable insights to both, the 13C-methionine breath test and the combined test. This pilot study evaluated middle-aged to older subjects (mean age 61 ± 16 years), reflecting peak disease prevalence. While appropriate for protocol validation, future studies should target younger individuals with early metabolic dysfunction for early intervention and prevention strategies. Despite these limitations, we believe the results of this study warrant further investigation in a larger patient population. This could include a randomized controlled trial with measurements taken both before and after an intervention, as well as comparisons with other invasive and non-invasive methods for assessing hepatic function and metabolic liver disease.
In summary, this pilot study demonstrates that combining a 13C-methionine breath test with a 75g OGTT substantially alters 13C-methionine kinetics, potentially due to delayed gastric emptying, while the OGTT diagnostic categorization remains preserved. When breath collection is extended to 145 minutes, cPDR values approach comparability to single-test protocols. These findings support the feasibility of a time-adjusted combined protocol for simultaneous metabolic assessment. Further studies are necessary to independently assess the validity of cPDR145min of the combined test compared to other liver assessment tools (e.g., transient elastography or liver biopsy) and formal validation against imaging/elastography standards, diagnostic accuracy quantification, and prospective outcome studies are required before clinical implementation as a screening tool.
Data availability statement
The data that support the findings of this study are available from the corresponding author, DRQ, upon reasonable request.
Ethics statement
The studies involving humans were approved by Ethics Committee of the Medical Faculty of Ruhr University Bochum, Bochum, Germany. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.
The authors want to thank B. Baller for the technical assistance in conducting the study experiments.
Conflict of interest
DQ has received honoraria for lectures, presentations, and educational events by Novo Nordisk and Eli Lilly & Co. and has received support for attending meetings and/or travel from Novo Nordisk, Eli Lilly & Co. and Boston Scientific. OC has received consulting fees from Olympus. AE has received honoraria for lectures and educational events by Olympus, Ovesco, Cook, Fujifilm, Falk Pharma, Pentax, Boston Scientific, MicroTech. WS has received consulting fees by Boehringer Ingelheim, Falk Foundation, Berlin Chemie, Eli Lilly & Co., Gilead, Novo Nordisk, Pfizer, Johnson & Johnson, BMS, Abbvie; has received honoraria for lectures, presentations or speakers bureaus from Boehringer Ingelheim, Falk Foundation, Berlin Chemie, Eli Lilly & Co., Novo Nordisk, BMS; has received Support for attending meetings and/or travel by Boehringer Ingelheim, Novo Nordisk, BMS, Pfizer and has participated on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim, Eli Lilly & Co., Berlin Chemie, Novo Nordisk and Johnson & Johnson.
The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2026.1780005/full#supplementary-material
ReferencesChewNWSNgCHTanDJHKongGLinCChinYH.
The global burden of metabolic disease: Data from 2000 to 2019. Cell Metab. (2023) 35:414–28 e3. doi: 10.1016/j.cmet.2023.02.003, PMID: 36889281StefanNCusiK.
A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. (2022) 10:284–96. doi: 10.1016/S2213-8587(22)00003-1, PMID: 35183303TarantinoGCostantiniSFinelliCCaponeFGuerrieroELa SalaN.
Carotid intima-media thickness is predicted by combined eotaxin levels and severity of hepatic steatosis at ultrasonography in obese patients with Nonalcoholic Fatty Liver Disease. PloS One. (2014) 9:e105610. doi: 10.1371/journal.pone.0105610, PMID: 25268946WuWWangMSunZWangXMiaoJZhengZ.
The predictive value of TNF-α and IL-6 and the incidence of macrovascular complications in patients with type 2 diabetes. Acta Diabetol. (2012) 49:3–7. doi: 10.1007/s00592-010-0198-0, PMID: 20495833MichalopoulouEThymisJLampsasSPavlidisGKatogiannisKVlachomitrosD.
The triad of risk: linking MASLD, cardiovascular disease and type 2 diabetes; from pathophysiology to treatment. J Clin Med. (2025) 14:428. doi: 10.3390/jcm14020428, PMID: 39860434FerdousSEFerrellJM.
Pathophysiological relationship between type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: novel therapeutic approaches. Int J Mol Sci. (2024) 25:8731. doi: 10.3390/ijms25168731, PMID: 39201418TantuMTFarhanaFZHaqueFKooKMQiaoLRossAG.
Pathophysiology, noninvasive diagnostics and emerging personalized treatments for metabolic associated liver diseases. NPJ Gut Liver. (2025) 2:18. https://doi.org/10.1038/s44355-025-00030-2FromentyBRodenM.
Mitochondrial alterations in fatty liver diseases. J Hepatol. (2023) 78:415–29. doi: 10.1016/j.jhep.2022.09.020, PMID: 36209983LiXChenWJiaZXiaoYShiAMaX.
Mitochondrial dysfunction as a pathogenesis and therapeutic strategy for metabolic-dysfunction-associated steatotic liver disease. Int J Mol Sci. (2025) 26:4256. doi: 10.3390/ijms26094256, PMID: 40362504ArmuzziAMarcocciaSZoccoMADe LorenzoAGriecoATondiP.
Non-Invasive assessment of human hepatic mitochondrial function through the 13C-methionine breath test. Scand J Gastroenterol. (2000) 35:650–3. doi: 10.1080/003655200750023633, PMID: 10912667SpahrLNegroFLeandroGMarinescuOGoodmanKJRubbia-BrandtL.
Impaired hepatic mitochondrial oxidation using the 13C-methionine breath test in patients with macrovesicular steatosis and patients with cirrhosis. Med Sci Monit. (2003) 9:CR6–11. https://pubmed.ncbi.nlm.nih.gov/12552242/, PMID: 12552242KorkmazHUnlerGKGokturkHSSchmidtWEKebapcilarL.
Noninvasive estimation of disease activity and liver fibrosis in nonalcoholic fatty liver disease using anthropometric and biochemical characteristics, including insulin, insulin resistance, and 13C-methionine breath test. Eur J Gastroenterol Hepatol. (2015) 27:1137–43. doi: 10.1097/MEG.0000000000000407, PMID: 26049707American Diabetes Association Professional Practice C.
2. Diagnosis and classification of diabetes: standards of care in diabetes-2024. Diabetes Care. (2024) 47:S20–42. doi: 10.2337/dc24-S002, PMID: 38078589BanaschMEllrichmannMTannapfelASchmidtWEGoetzeO.
The non-invasive (13)C-methionine breath test detects hepatic mitochondrial dysfunction as a marker of disease activity in non-alcoholic steatohepatitis. Eur J Med Res. (2011) 16:258–64. doi: 10.1186/2047-783X-16-6-258, PMID: 21810560Vallet-PichardAMalletVNalpasBVerkarreVNalpasADhalluin-VenierV.
FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. (2007) 46:32–6. doi: 10.1002/hep.21669, PMID: 17567829BanaschMEmminghausREllrichmannMSchmidtWEGoetzeO.
Longitudinal effects of hepatitis C virus treatment on hepatic mitochondrial dysfunction assessed by C-methionine breath test. Aliment Pharmacol Ther. (2008) 28:443–9. doi: 10.1111/j.1365-2036.2008.03745.x, PMID: 18513202TangQLiXSongPXuL.
Optimal cut-off values for the homeostasis model assessment of insulin resistance (HOMA-IR) and pre-diabetes screening: Developments in research and prospects for the future. Drug Discov Ther. (2015) 9:380–5. doi: 10.5582/ddt.2015.01207, PMID: 26781921TahaparyDLPratisthitaLBFitriNAMarcellaCWafaSKurniawanF.
Challenges in the diagnosis of insulin resistance: Focusing on the role of HOMA-IR and Tryglyceride/glucose index. Diabetes Metab Syndr. (2022) 16:102581. doi: 10.1016/j.dsx.2022.102581, PMID: 35939943LemaitreRNYuCHoofnagleAHariNJensenPNFrettsAM.
Circulating sphingolipids, insulin, HOMA-IR, and HOMA-B: the strong heart family study. Diabetes. (2018) 67:1663–72. doi: 10.2337/db17-1449, PMID: 29588286BharuchaAECamilleriMVeilEBurtonDZinsmeisterAR.
Comprehensive assessment of gastric emptying with a stable isotope breath test. Neurogastroenterol Motil. (2013) 25:e60–9. doi: 10.1111/nmo.12054, PMID: 23216872XieCHuangWWangXTrahairLGPhamHTMaratheCS.
Gastric emptying in health and type 2 diabetes: An evaluation using a 75 g oral glucose drink. Diabetes Res Clin Pract. (2021) 171:108610. doi: 10.1016/j.diabres.2020.108610, PMID: 33301790FaulFErdfelderELangAGBuchnerA.
G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. (2007) 39:175–91. doi: 10.3758/BF03193146, PMID: 17695343European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO).
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. (2024). doi: 10.1016/j.jhep.2024.04.031, PMID: 38851997ChandlerTLWhiteHM.
Glucose metabolism is differentially altered by choline and methionine in bovine neonatal hepatocytes. PloS One. (2019) 14:e0217160. doi: 10.1371/journal.pone.0217160, PMID: 31141525JallehRJJonesKLRaynerCKMaratheCSWuTHorowitzM.
Normal and disordered gastric emptying in diabetes: recent insights into (patho)physiology, management and impact on glycaemic control. Diabetologia. (2022) 65:1981–93. doi: 10.1007/s00125-022-05796-1, PMID: 36194250StevensJEJonesKLRaynerCKHorowitzM.
Pathophysiology and pharmacotherapy of gastroparesis: current and future perspectives. Expert Opin Pharmacother. (2013) 14:1171–86. doi: 10.1517/14656566.2013.795948, PMID: 23663133PhillipsLKDeaneAMJonesKLRaynerCKHorowitzM.
Gastric emptying and glycaemia in health and diabetes mellitus. Nat Rev Endocrinol. (2015) 11:112–28. doi: 10.1038/nrendo.2014.202, PMID: 25421372BrenerWHendrixTRMcHughPR.
Regulation of the gastric emptying of glucose. Gastroenterology. (1983) 85:76–82. doi: 10.1016/S0016-5085(83)80232-7, PMID: 6852464TargherGBertoliniLPadovaniRRodellaSZoppiniGZenariL.
Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care. (2006) 29:1325–30. doi: 10.2337/dc06-0135, PMID: 16732016European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Obes Facts. (2024) 17:374–443. doi: 10.1159/000539371, PMID: 38852583Krupková-MeixnerováLVeseláKVitováAJanosíkováBAndelMKozichV.
Methionine-loading test: evaluation of adverse effects and safety in an epidemiological study. Clin Nutr. (2002) 21:151–6. doi: 10.1054/clnu.2001.0523, PMID: 12056788ArcherAJBelfieldKJOrrJGGordonFHAbeysekeraKW.
EASL clinical practice guidelines: non-invasive liver tests for evaluation of liver disease severity and prognosis. Frontline Gastroenterol. (2022) 13:436–9. doi: 10.1136/flgastro-2021-102064, PMID: 36051951LeeJValiYBoursierJSpijkerRAnsteeQMBossuytPM.
Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. Liver Int. (2021) 41:261–70. doi: 10.1111/liv.14669, PMID: 32946642OzturkAOlsonMCSamirAEVenkateshSK.
Liver fibrosis assessment: MR and US elastography. Abdom Radiol (NY). (2022) 47:3037–50. doi: 10.1007/s00261-021-03269-4, PMID: 34687329Di CiaulaACalamitaGShanmugamHKhalilMBonfrateLWangDQ.
Mitochondria matter: systemic aspects of nonalcoholic fatty liver disease (NAFLD) and diagnostic assessment of liver function by stable isotope dynamic breath tests. Int J Mol Sci. (2021) 22:7702. doi: 10.3390/ijms22147702, PMID: 34299321MilazzoLPiazzaMSangalettiOGattiNCappellettiAAdorniF.
13C]Methionine breath test: a novel method to detect antiretroviral drug-related mitochondrial toxicity. J Antimicrob Chemother. (2005) 55:84–9. doi: 10.1093/jac/dkh497, PMID: 15590719PowellEEWongVWRinellaM.
Non-alcoholic fatty liver disease. Lancet. (2021) 397:2212–24. doi: 10.1016/S0140-6736(20)32511-3, PMID: 33894145
Edited by: Bo Zhu, Harvard Medical School, United States
Reviewed by: Giovanni Tarantino, University of Naples Federico II, Italy